Skip to main content

Table 2 NSAID, glucocorticoid, and DMARD therapy in SpA with and without TB

From: Risk of tuberculosis in patients with spondyloarthritis: data from a centralized electronic database in Hong Kong

 

SpA with TB

SpA without TB

P value

NSAIDs

43/43 (100.0%)

2783/2926 (95.1%)

0.14

glucocorticoid therapy > 6 months

6/43 (14.0%)

148/2926 (5.1%)

0.01

DMARDs

29/43 (67.4%)

1831/2926 (62.6%)

0.51

cDMARDs

21/43 (48.8%)

1609/2926 (55.0%)

0.42

sulfasalazine

16/43 (37.2%)

1253/2926 (42.8%)

0.46

methotrexate

9/43 (20.9%)

763/2926 (26.1%)

0.45

leflunomide

0/43 (0.0%)

156/2926 (5.3%)

0.12

bDMARDs

17/43 (39.5%)

709/2926 (24.2%)

0.02

TNFi

17/43 (39.5%)

666/2926 (22.8%)

0.001

infliximab

10/43 (23.3%)

98/2926 (3.3%)

< 0.001

etanercept

2/43 (4.7%)

268/2926 (9.2%)

0.31

adalimumab

5/43 (11.6%)

235/2926 (8.0%)

0.39

golimumab

0/43 (0.0%)

196/2926 (6.7%)

0.08

certolizumab

0/43 (0.0%)

39/2926 (1.3%)

0.45

secukinumab

0/43 (0.0%)

69/2926 (2.4%)

0.31

ustekinumab

0/43 (0.0%)

19/2926 (0.6%)

0.60

  1. NSAID Non-steroidal anti-inflammatory drug; SpA Spondyloarthritis; TB Tuberculosis; DMARDs Disease modifying anti-rheumatic drugs; cDMARDs Conventional disease modifying antirheumatic drugs; bDMARDs Biologic disease modifying antirheumatic drugs; TNFi Tumour necrosis factor inhibitor